1. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis
- Author
-
Dongyu Zhang, Neil Shah, Michael Cook, Matthew Blackburn, Michael Serzan, Shailesh Advani, Arnold Potosky, Subha Madhavan, Anas Belouali, Michael Atkins, and Dejana Braithwaite
- Subjects
immune checkpoint inhibitor ,body mass index ,immune-related adverse events ,epidemiology ,Cancer Research ,Oncology ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Article ,RC254-282 - Abstract
Simple Summary Currently, clinical studies exploring the impact of high body fat on toxicities after receiving immune checkpoint inhibitors (ICIs) among cancer patients are limited. Here, we analyze data from a health care system serving the mid-Atlantic geographic region to assess how body fat can affect the development of toxicities of ICIs. In our study, body mass index (BMI) was used as the measure of body fat, and the results suggested that cancer patients with a high BMI were more likely to have toxicities after receiving ICIs. Our study suggests that symptom management should be incorporated in the cancer care continuum of patients who receive ICIs, especially those with high BMI. In clinical settings, oncologists should inform cancer patients receiving ICIs with high BMI that their risk of post-treatment toxicities can be higher compared to their counterparts with lower BMI. Abstract Evidence regarding the association between body mass index (BMI) and immune-related adverse events (irAEs) among cancer patients receiving immune checkpoint inhibitors (ICIs) is limited. Here, we use cross-sectional hospital-based data to explore their relationship. Pre-treatment BMI was treated as an ordinal variable (
- Published
- 2021